Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

November 28, 2022

Study Completion Date

December 13, 2025

Conditions
Central Chondrosarcoma, Grade 2Central Chondrosarcoma, Grade 3Dedifferentiated ChondrosarcomaMetastatic Clear Cell Sarcoma of Soft TissueMetastatic Primary Central ChondrosarcomaUnresectable Primary Central Chondrosarcoma
Interventions
DRUG

Atezolizumab

Given IV

PROCEDURE

Biopsy Procedure

Correlative studies

PROCEDURE

Biospecimen Collection

Correlative studies

PROCEDURE

Computed Tomography

Undergo CT scan

Trial Locations (15)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

20892

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

National Institutes of Health Clinical Center, Bethesda

NCI - Center for Cancer Research, Bethesda

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

32610

University of Florida Health Science Center - Gainesville, Gainesville

37232

Vanderbilt University/Ingram Cancer Center, Nashville

43210

Ohio State University Comprehensive Cancer Center, Columbus

63110

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center-South County, St Louis

77030

M D Anderson Cancer Center, Houston

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

02215

Dana-Farber Cancer Institute, Boston

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH